Literature DB >> 31254849

Increasing support by nasal high flow acutely modifies the ROX index in hypoxemic patients: A physiologic study.

Tommaso Mauri1, Eleonora Carlesso2, Elena Spinelli3, Cecilia Turrini4, Francesca Dalla Corte4, Riccarda Russo3, Jean-Damien Ricard5, Antonio Pesenti6, Oriol Roca7, Giacomo Grasselli6.   

Abstract

The ROX (Respiratory rate-OXygenation) index is an early predictor of failure of nasal high flow (NHF), with lower values indicating higher risk of intubation. We measured the ROX index at set flow rate of 30 and 60 l/min in 57 hypoxemic patients on NHF. Patients with increased ROX index values at higher flow (n = 40) showed worse baseline oxygenation, higher respiratory rate and lower ROX index in comparison to patients with unchanged or decreased ROX index values (n = 17). The ROX index variation between flows was correlated with the change in end expiratory lung volume. Set flow rate during NHF might impact the ROX index value.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute hypoxemic respiratory failure; Electrical impedance tomography; Monitoring; Nasal high flow

Mesh:

Year:  2019        PMID: 31254849     DOI: 10.1016/j.jcrc.2019.06.020

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Predicting nasal high-flow therapy failure by pediatric respiratory rate-oxygenation index and pediatric respiratory rate-oxygenation index variation in children.

Authors:  Dincer Yildizdas; Ahmet Yontem; Gokce Iplik; Ozden Ozgur Horoz; Faruk Ekinci
Journal:  Eur J Pediatr       Date:  2020-10-19       Impact factor: 3.183

2.  The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study.

Authors:  Gregory L Calligaro; Usha Lalla; Gordon Audley; Phindile Gina; Malcolm G Miller; Marc Mendelson; Sipho Dlamini; Sean Wasserman; Graeme Meintjes; Jonathan Peter; Dion Levin; Joel A Dave; Ntobeko Ntusi; Stuart Meier; Francesca Little; Desiree L Moodley; Elizabeth H Louw; Andre Nortje; Arifa Parker; Jantjie J Taljaard; Brian W Allwood; Keertan Dheda; Coenraad F N Koegelenberg
Journal:  EClinicalMedicine       Date:  2020-10-06

3.  Prediction of high-flow nasal cannula outcomes at the early phase using the modified respiratory rate oxygenation index.

Authors:  Zhe Li; Chen Chen; Zhangjun Tan; Yulong Yao; Shunpeng Xing; Yan Li; Yuan Gao; Zhanqi Zhao; Yuxiao Deng; Mingli Zhu
Journal:  BMC Pulm Med       Date:  2022-06-13       Impact factor: 3.320

4.  Nasal high flow higher than 60 L/min in patients with acute hypoxemic respiratory failure: a physiological study.

Authors:  Maria Cristina Basile; Tommaso Mauri; Elena Spinelli; Francesca Dalla Corte; Giacomo Montanari; Ines Marongiu; Savino Spadaro; Alessandro Galazzi; Giacomo Grasselli; Antonio Pesenti
Journal:  Crit Care       Date:  2020-11-23       Impact factor: 9.097

5.  Role of ROX index in the first assessment of COVID-19 patients in the emergency department.

Authors:  Alice Gianstefani; Gabriele Farina; Veronica Salvatore; Francesca Alvau; Maria Laura Artesiani; Sara Bonfatti; Francesca Campinoti; Ilaria Caramella; Michele Ciordinik; Andrea Lorusso; Sara Nanni; Daniela Nizza; Stefano Nava; Fabrizio Giostra
Journal:  Intern Emerg Med       Date:  2021-03-01       Impact factor: 3.397

Review 6.  Rationale and limitations of the SpO2/FiO2 as a possible substitute for PaO2/FiO2 in different preclinical and clinical scenarios.

Authors:  Eduardo Butturini de Carvalho; Thiago Ravache Sobreira Leite; Raquel Ferreira de Magalhães Sacramento; Paulo Roberto Loureiro do Nascimento; Cynthia Dos Santos Samary; Patrícia Rieken Macedo Rocco; Pedro Leme Silva
Journal:  Rev Bras Ter Intensiva       Date:  2022 Jan-Mar

7.  Effect of postextubation high-flow nasal cannula therapy on lung recruitment and overdistension in high-risk patient.

Authors:  Rui Zhang; Huaiwu He; Long Yun; Xiang Zhou; Xu Wang; Yi Chi; Siyi Yuan; Zhanqi Zhao
Journal:  Crit Care       Date:  2020-03-06       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.